Brief: HLS Therapeutics Announces Health Canada Approval For Vascepa To Reduce Risk Of Cardiovascular Events
31/12/2019 19:22
Dec 31 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS ANNOUNCES HEALTH CANADA APPROVAL FOR
VASCEPA®
TO REDUCE THE RISK OF CARDIOVASCULAR EVENTS
* HLS THERAPEUTICS INC - COMMERCIAL LAUNCH FOR VASCEPA IN
CANADA
EXPECTED TO TAKE PLACE IN MID-FEBRUARY 2020 TIMEFRAME
Source text for Eikon: ID:nCNWPsCkTa
Further company coverage: HLS.TO
((Reuters.briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsBrief: Hls Therapeutics Increases Normal Course Issuer Bid
Brief: HLS Therapeutics Announces Q2 2026 Financial Results
Canada's HLS Therapeutics Q2 revenue rises on higher cardiovascular drugs demand
Brief: HLS Therapeutics - Secures Nilemdo Reimbursement With Private Payers Covering 80% Of Privately Insured Canadians
Canada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group